142 related articles for article (PubMed ID: 14679144)
1. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Konecny GE; Wilson CA; Slamon DJ
J Natl Cancer Inst; 2003 Dec; 95(24):1813-5. PubMed ID: 14679144
[No Abstract] [Full Text] [Related]
2. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
3. Getting to grips with gefitinib.
Renee Bailey L; Janas M
Lancet Oncol; 2003 Dec; 4(12):719-20. PubMed ID: 14662427
[No Abstract] [Full Text] [Related]
4. EGFR inhibitors: clinical results.
De Marinis F; Nelli F; D'Auria G
Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893
[No Abstract] [Full Text] [Related]
5. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML; Giaccone G
Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors.
Wakeling AE
Curr Opin Pharmacol; 2002 Aug; 2(4):382-7. PubMed ID: 12127870
[TBL] [Abstract][Full Text] [Related]
7. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
8. BAD: a good therapeutic target?
Motoyama AB; Hynes NE
Breast Cancer Res; 2003; 5(1):27-30. PubMed ID: 12559042
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Kiguchi K; Ruffino L; Kawamoto T; Ajiki T; Digiovanni J
Clin Cancer Res; 2005 Aug; 11(15):5572-80. PubMed ID: 16061875
[TBL] [Abstract][Full Text] [Related]
10. The ErbB receptor family: a therapeutic target for cancer.
de Bono JS; Rowinsky EK
Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
[TBL] [Abstract][Full Text] [Related]
11. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer.
Arteaga CL; Truica CI
Semin Oncol; 2004 Feb; 31(1 Suppl 3):3-8. PubMed ID: 15052538
[TBL] [Abstract][Full Text] [Related]
13. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
Maiello MR; D'Alessio A; De Luca A; Carotenuto A; Rachiglio AM; Napolitano M; Cito L; Guzzo A; Normanno N
Breast Cancer Res Treat; 2007 May; 102(3):275-82. PubMed ID: 17004112
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
15. Severe acute interstitial pnuemonia and gefitinib.
Sumpter K; Harper-Wynne C; O'Brien M; Congleton J
Lung Cancer; 2004 Mar; 43(3):367-8. PubMed ID: 15165098
[No Abstract] [Full Text] [Related]
16. Apparent adverse drug reactions prompt concern about Iressa.
Schultz J
J Natl Cancer Inst; 2003 Apr; 95(8):577-9. PubMed ID: 12697847
[No Abstract] [Full Text] [Related]
17. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Zorzou MP; Stratigos A; Efstathiou E; Bamias A
Acta Derm Venereol; 2004; 84(4):308-9. PubMed ID: 15339078
[No Abstract] [Full Text] [Related]
18. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
[TBL] [Abstract][Full Text] [Related]
20. Overview of tyrosine kinase inhibitors in clinical breast cancer.
Agrawal A; Gutteridge E; Gee JM; Nicholson RI; Robertson JF
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S135-44. PubMed ID: 16113090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
